hpk1

HPK1-IN-51, serving as a PROTAC target protein ligand (Ligands for Target Protein for PROTACs), is utilized in synthesis processes.

HPK1-IN-47, a PROTAC HPK1 degrader (DC 50: 23 nM in PBMCs), serves as a precursor for the synthesis of compounds like PROTAC HPK1 Degrader-2. It is utilized in research focused on diseases mediated by HPK1, including cancer.

HPK1-IN-53 (compound 3a) is the most potent inhibitor of HPK1, exhibiting an IC50 value of 48 nM.

HPK1-IN-52 is an effective orally active hematopoietic progenitor kinase 1 (HPK1) inhibitor, displaying anti-tumor activity with an IC50 value of 10.4 nM.

HPK1 Ligand 2 is a PROTAC target protein ligand (Ligand for Target Protein for PROTAC). It is utilized in the synthesis of DD205-291.

HPK1-IN-54 (Compound 16) is a potent inhibitor of HPK1 (hematopoietic progenitor kinase 1), enhancing T cell activation and proliferation by blocking HPK1 activity to exert antitumor effects. It has an IC50 of 2.67 nM for HPK1, showing excellent selectivity over the MAP4K family (>100-fold) and other selected kinases (>300-fold). HPK1-IN-54 exhibits moderate in vivo clearance and reasonable oral exposure in both mice and rats. Additionally, in the CT26 mouse colon cancer model, HPK1-IN-54 demonstrates significant antitumor activity and shows a synergistic effect when combined with anti-PD-1 therapy. HPK1-IN-54 holds promise for research in the field of immunology.

HPK1-IN-55 (compound 19) is a selective and orally active inhibitor of hematopoietic progenitor kinase 1 (HPK1) with an IC50 of less than 0.51 nM. It exhibits exceptional kinase selectivity, being over 637 times more selective for HPK1 compared to GCK kinase and over 1022 times compared to LCK. HPK1-IN-55 possesses anti-cancer properties.

HPK1-IN-56 (Compound A29) is an HPK1 inhibitor with an IC50 of 2.70 nM. It inhibits downstream p-SLP76 in Jurkat T cells with an IC50 of 8.1 nM. Additionally, HPK1-IN-56 induces IL-2 production in human PBMCs. This compound exhibits anticancer properties, enhancing T cell cytotoxicity and the antitumor efficacy of anti-PD-1 antibodies.

HPK1-IN-19 is an inhibitor of hematopoietic progenitor kinase 1 (HPK1).

HPK1-IN-19 is a potent inhibitor of hematopoietic progenitor kinase 1 (HPK1).

HPK1-IN-4 is an HPK1 (MAPK41) inhibitor with an IC 50 of 0.061 nM. HPK1-IN-4 is often used as a preclinical immunotherapy tool compound.

HPK1-IN-24 (example 51) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor (Ki = 100 nM) with potential applications in cancer research [1].

HPK1-IN-26, a novel compound, is a potent inhibitor of both HPK1 and GLK. This small molecule exhibits promise in aiding the study of animal pathogen infection [1].

HPK1-IN-25 (example 94), an inhibitor of hematopoietic progenitor kinase 1 (HPK1), demonstrates enzymatic activity with an IC50 value of 129 nM, indicating its potential utility in cancer research [1].

HPK1-IN-30 is a potent inhibitor of HPK1 with potential applications in cancer disease research.

HPK1-IN-17 is a selective and potent inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPK1) is a member of the MAP4Ks family and was originally cloned from hematopoietic progenitor cells. HPK1-IN-17 can be used to study, prevent or ameliorate diseases or conditions associated with HPK1 activity (e.g., cancer).

HPK1-IN-12 is a potent inhibitor of HPK1. HPK1-IN-12 has potential for the study of HPK1-related diseases.

HPK1-IN-13 is a potent inhibitor of HPK1. HPK1-IN-12 has potential for the study of HPK1-related diseases.

HPK1-IN-21 is a potent, orally active HPK1 kinase inhibitor with a Ki value of 0.8 nM.

HPK1-IN-14 is a potent inhibitor of HPK1. HPK1-IN-14 has potential for the study of HPK1-related diseases.